Edition:
United States

Elanix Biotechnologies AG (ELNk.F)

ELNk.F on Frankfurt Stock Exchange

6.43EUR
28 Apr 2017
Change (% chg)

€0.09 (+1.34%)
Prev Close
€6.35
Open
€6.20
Day's High
€6.44
Day's Low
€6.20
Volume
5,485
Avg. Vol
46,097
52-wk High
€8.30
52-wk Low
€1.34

Latest Key Developments (Source: Significant Developments)

Elanix Biotechnologies FY EBIT loss narrows to 2.7 million euros
Tuesday, 18 Apr 2017 02:08am EDT 

April 18 - Elanix Biotechnologies AG ::Said on Saturday preliminary FY EBITDA according to IFRS amounts to a loss of 1.3 million euros ($1.38 million) (2015: minus 1.8 million euros).FY Group EBIT amounted to minus 2.7 million euros (2015: minus 3.2 million euros).Group sales are expected to increase to 0.3 - 0.5 million euros, so that a negative group operating result (EBIT) of 3.5 - 4.0 million euros is expected again in 2017.Provided that it is possible to raise an additional 10 to 20 million euros by means of suitable capital measures, a positive result is expected in the next financial year (2019).  Full Article

Elanix Biotechnologies says capital increase successfully placed
Friday, 24 Feb 2017 11:42am EST 

Elanix Biotechnologies AG :Capital increase successfully placed, gross issuing proceeds amount to some 4.76 million euros ($5.04 million).  Full Article

Elanix Biotechnologies: CEO informs about planned cash capital increase
Friday, 13 Jan 2017 08:34am EST 

Elanix Biotechnologies AG : CEO informs about planned cash capital increase with indirect subscription rights .CEO will inform about details of planned capital increase in a timely manner.  Full Article

Elanix Biotechnologies announces non-binding letter of intent with Oxford MEStar Ltd
Tuesday, 22 Nov 2016 04:00am EST 

Elanix Biotechnologies AG :Elanix Biotechnologies announces non-binding letter of intent with Oxford MEStar Ltd in regard to setting up a JV to market GynRepair in China.  Full Article

Elanix Biotechnologies: unit buys 100% of equity of Repair-A SA
Monday, 3 Oct 2016 02:13am EDT 

Elanix Biotechnologies AG : Said on Friday its subsidiary Elanix-Technologies SA acquires 100 percent of equity of Repair-A SA .It has been agreed not to disclose the sum involved.  Full Article

Elanix Biotechnologies says fully placed capital increase
Thursday, 11 Aug 2016 05:17am EDT 

Elanix Biotechnologies AG : Fully placed capital increase . Net proceeds from the capital increase will be used in particular for the introduction of new products .Gross proceeds of about 1.2 million euros ($1.34 million).  Full Article

Elanix Biotechnologies decides on capital increase
Monday, 1 Aug 2016 01:22am EDT 

Elanix Biotechnologies AG : Said on Friday decided on capital increase from authorized capital against cash contributions by 405,000 shares under exclusion of subscription rights . Issue price of 3.00 euros ($3.35)per share . Share capital will be increased by 405,000.00 euros to 5,666,000.00 euros .Company should receive 1,215,000.00 euros from capital increase.  Full Article

Elanix Biotechnologies AG decides on capital increase
Friday, 15 Apr 2016 04:01am EDT 

Elanix Biotechnologies AG:Decides on capital increase.To increase capital of company by up to 500,000 euros ($562,700.00) to up to 5,666,000 euros by issuing up to 500,000 new shares.Subscription price of 3.00 euros per new share.  Full Article

Porta Systems AG says AGM creates conditions for reorientation as biotechnology company, to change name to Elanix Biotechnologies AG
Thursday, 24 Sep 2015 02:30pm EDT 

Porta Systems AG:Annual General Meeting decided to change name of company to "Elanix Biotechnologies AG" and to relocate company's headquarters to Berlin.Decided to amend statutory corporate purpose and to revise core to production and distribution of products, other operation and provision of services in fields of healthcare, medicine, cosmetics and biotechnology.  Full Article

More From Around the Web

BRIEF-Elanix Biotechnologies announces non-binding letter of intent with Oxford MEStar Ltd

* Elanix Biotechnologies announces non-binding letter of intent with Oxford MEStar Ltd in regard to setting up a JV to market GynRepair in China Source text for Eikon: Further company coverage: (Gdynia Newsroom)

No consensus analysis data available.